Characterizing the effects of atypical antipsychotics on the neutrophil model cell line, PLB-985
Emily J. Robbs
University of West Florida,
Master of Science (MS), University of West Florida
2021
Metrics
429 File views/ downloads
51 Record Views
Abstract
Atypical antipsychotics (AAPs) are a class of drug used to treat several mental diseases like bipolar disorder, obsessive-compulsive disorder, and schizophrenia. However, these substances are also known to cause a rare, yet severe and sometimes fatal syndrome known as neutropenia. Neutropenia (and its more acute form, agranulocytosis) is characterized by a significant decrease in an individual's circulating neutrophils--the most abundant white blood cell. Neutrophils are essential for proper innate immunity, and depletion can result in higher risk of developing life-threatening illnesses. How atypical antipsychotics induce neutropenia is not well-understood, though research is ongoing. In this study, we aim to characterize the effects of four AAPs--clozapine, olanzapine, quetiapine and aripiprazole--on PLB-985 cell viability, as assessed by the XTT Cell Viability Assay. We found that only aripiprazole is able to significantly decrease dPLB-985 cell viability after 48-hour treatment. We hypothesized that aripiprazole's negative effect on cell viability is through its unique mechanism of action as a partial dopamine agonist; however, our results suggest that aripiprazole's effects are independent of dopamine receptor agonism.